Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Endometrial cancer (mmu05213)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Apc
KLA  ATP  ATP+KLA
 NM_007462 adenomatosis polyposis coli (Apc), mRNA [NM_007462] KLA .98 .94 .91 .86 .83 .91 1.01
ATP 1.06 1.16 1.04 .97 1.63 1.50 1.25
KLA/ATP 1.01 1.01 .92 .88 1.22 1.46 1.21
Apc2
KLA  ATP  ATP+KLA
 NM_011789 adenomatosis polyposis coli 2 (Apc2), mRNA [NM_011789] KLA 1.05 1.15 1.12 1.13 1.07 1.11 1.08
ATP 1.04 .97 1.15 1.27 1.12 1.09 1.16
KLA/ATP 1.12 1.20 1.21 1.24 1.25 1.13 1.04
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Axin1
KLA  ATP  ATP+KLA
 NM_009733 axin 1 (Axin1), mRNA [NM_009733] KLA .97 .91 1.14 1.08 1.23 1.21 1.07
ATP 1.08 1.06 .96 1.04 1.56 1.30 1.13
KLA/ATP 1.05 1.03 1.06 1.03 1.43 1.45 1.21
Axin2
KLA  ATP  ATP+KLA
 NM_015732 axin2 (Axin2), mRNA [NM_015732] KLA .91 .97 1.00 .97 1.00 .97 1.00
ATP .99 .97 .97 1.04 1.12 .98 1.01
KLA/ATP .98 .86 1.25 1.04 1.09 1.01 1.06
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Casp9
KLA  ATP  ATP+KLA
 NM_015733 caspase 9 (Casp9), mRNA [NM_015733] KLA .31 .31 .40 .66 .89 1.19 .91
ATP .88 .77 .91 .59 .43 .75 .93
KLA/ATP .26 .26 .30 .28 .80 1.06 .97
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Cdh1
KLA  ATP  ATP+KLA
 NM_009864 cadherin 1 (Cdh1), mRNA [NM_009864] KLA 1.03 1.03 .99 .94 .95 .97 .99
ATP 1.04 1.06 1.06 .96 .99 1.07 .95
KLA/ATP 1.02 1.07 1.00 .90 .93 .94 .98
Ctnna1
KLA  ATP  ATP+KLA
 AK008121 adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010005H04 product:unclassifiable, full insert sequence. [AK008121] KLA .82 .76 .72 .81 .94 .74 .80
ATP 1.08 1.01 .51 .57 2.45 1.25 .95
KLA/ATP .91 .82 .76 .58 1.58 1.01 .92
Ctnna1
KLA  ATP  ATP+KLA
 NM_009818 catenin (cadherin associated protein), alpha 1 (Ctnna1), mRNA [NM_009818] KLA .97 .91 1.06 .84 .75 .52 .56
ATP 1.09 1.14 1.00 .86 .80 .98 .83
KLA/ATP 1.02 1.07 .90 .80 .66 .59 .57
Ctnna2
KLA  ATP  ATP+KLA
 AK035033 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430076K22 product:hypothetical Vinculin and alpha-catenin containing protein, full insert sequence [AK035033] KLA 1.05 1.11 1.12 1.05 1.02 1.04 1.19
ATP .99 .97 1.00 1.05 1.02 1.05 1.03
KLA/ATP 1.11 1.06 1.01 1.12 1.06 1.02 1.03
Ctnna3
KLA  ATP  ATP+KLA
 AK029664 adult male testis cDNA, RIKEN full-length enriched library, clone:4930438F12 product:unclassifiable, full insert sequence. [AK029664] KLA 1.03 1.06 .99 1.05 .95 1.01 1.04
ATP 1.03 1.05 1.02 1.04 .99 1.03 1.05
KLA/ATP 1.01 1.00 .99 1.01 1.00 .98 1.05
Ctnna3
KLA  ATP  ATP+KLA
 NM_177612 catenin (cadherin associated protein), alpha 3 (Ctnna3), mRNA [NM_177612] KLA 1.01 1.06 .98 1.04 1.03 1.04 1.07
ATP .96 1.02 .94 1.11 1.02 1.09 .91
KLA/ATP 1.01 .94 .94 1.10 1.10 1.04 1.04
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Foxo3a
KLA  ATP  ATP+KLA
 AK079567 adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230087I01 product:unclassifiable, full insert sequence. [AK079567] KLA .82 .81 .91 .83 .86 .86 .81
ATP .98 1.00 1.13 1.03 .97 .90 .82
KLA/ATP .86 .80 .90 .99 1.07 .84 .73
Foxo3a
KLA  ATP  ATP+KLA
 NM_019740 forkhead box O3a (Foxo3a), mRNA [NM_019740] KLA .94 .92 .86 .97 .87 1.04 1.04
ATP .99 1.09 1.06 .97 .96 1.07 1.15
KLA/ATP .90 .79 .90 .99 .95 1.04 1.11
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Ilk
KLA  ATP  ATP+KLA
 NM_010562 integrin linked kinase (Ilk), mRNA [NM_010562] KLA .84 .85 .92 .81 .97 .96 .67
ATP 1.03 1.11 .85 1.07 .82 .66 .91
KLA/ATP .93 .90 .58 .94 .63 .63 .80
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lef1
KLA  ATP  ATP+KLA
 NM_010703 lymphoid enhancer binding factor 1 (Lef1), mRNA [NM_010703] KLA 1.00 1.05 1.00 1.05 1.01 1.07 1.07
ATP .96 .98 1.03 1.09 .99 1.04 1.00
KLA/ATP 1.02 .98 .95 1.08 1.02 1.16 1.08
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mlh1
KLA  ATP  ATP+KLA
 NM_026810 mutL homolog 1 (E. coli) (Mlh1), mRNA [NM_026810] KLA .58 .55 .46 .47 .38 .49 .66
ATP .93 .95 1.06 1.02 .50 .80 .77
KLA/ATP .59 .56 .59 .55 .41 1.31 1.86
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.45680
7
KLA  ATP  ATP+KLA
 157951728 Unknown KLA 1.00 1.02 1.05 .97 .99 .96 1.05
ATP 1.13 .98 1.00 1.06 1.02 .94 .98
KLA/ATP 1.11 .96 1.08 1.01 .99 1.01 .98
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.71710
KLA  ATP  ATP+KLA
 158966712 Unknown KLA 1.23 1.26 1.52 1.32 1.46 1.45 1.38
ATP .98 1.07 1.18 1.51 1.49 1.15 1.18
KLA/ATP 1.27 1.45 1.29 1.61 1.65 1.41 1.54
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pdpk1
KLA  ATP  ATP+KLA
 NM_011062 3-phosphoinositide dependent protein kinase-1 (Pdpk1), transcript variant 1, mRNA [NM_011062] KLA .90 .90 .84 1.00 1.32 1.19 1.15
ATP 1.05 1.09 1.04 1.14 1.31 .97 1.17
KLA/ATP .90 .89 .91 1.02 1.27 .96 1.42
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pten
KLA  ATP  ATP+KLA
 NM_008960 phosphatase and tensin homolog (Pten), mRNA [NM_008960] KLA .79 .73 .61 .59 .56 .70 1.00
ATP 1.04 1.11 1.07 1.12 1.03 1.38 .83
KLA/ATP .75 .69 .60 .74 .93 1.09 1.24
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Tcf3
KLA  ATP  ATP+KLA
 NM_001079822 transcription factor 3 (Tcf3), transcript variant 1, mRNA [NM_001079822] KLA 1.03 .98 1.01 .98 .98 1.03 1.01
ATP 1.00 1.02 1.00 1.06 1.10 1.07 .99
KLA/ATP 1.07 .99 .97 1.05 1.05 1.11 .96
Tcf7
KLA  ATP  ATP+KLA
 NM_009331 transcription factor 7, T-cell specific (Tcf7), mRNA [NM_009331] KLA 1.00 1.01 1.03 1.00 .98 1.01 1.07
ATP .99 .98 1.02 1.03 1.03 1.00 1.01
KLA/ATP 1.00 1.03 1.04 1.02 1.04 1.02 1.00
Tcf7l2
KLA  ATP  ATP+KLA
 NM_009333 transcription factor 7-like 2, T-cell specific, HMG-box (Tcf7l2), mRNA [NM_009333] KLA 1.01 1.12 1.11 1.31 1.06 1.34 1.29
ATP 1.04 1.05 .94 1.06 .90 .81 .96
KLA/ATP 1.08 1.11 1.05 1.18 1.04 1.02 1.42
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74